Pubertal Development in Patients with RASopathies
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Age of pubertal onset in males and females in all different genotypes
研究概览
简要总结
Retrospective, single-centre, non-profit, observational study on pubertal development in patients with RASopathies.
Literature data shows that puberty can be delayed by about 2 years in patients with RASopathies and this has been associated with a reduced peak growth rate. To date, only a few numerically limited case series without molecular characterisation have been published.
This descriptive study should improve knowledge of pubertal development and its influence on growth and final stature. The primary aims are to describe the age of onset and progression of pubertal development in the cohort of patients with RASopathies, both male and female, and to describe the influence of pubertal development on statural growth and final stature in the same cohort.
详细描述
The study enrolls patients with molecularly confirmed RASopathy and completed pubertal development who referred to the Centre for Rare Congenital-Malformative Diseases of the Pediatrics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy, between 01/01/2001 and 31/12/2023. Being a Regional Centre, it is possible to enrol a significant number of patients.
The primary aims of the study are to describe the age of onset and progression of pubertal development in this cohort of patients, and to describe the influence of pubertal development on statural growth and final stature. The secondary aim is to compare the trends of pubertal development and statural growth at puberty in GH-treated and untreated patients with RASopathies.
The study consists of the retrospective collection and analysis of anthropometric data on growth and pubertal development of the cohort of patients enrolled by consulting their medical records. More in detail, for each patient will be collected demographic data, prenatal data, personal medical history, pubertal history, organ involvement data, outpatient clinical evaluation with height, weight, and growth rate, data on GH therapy, if any, radiological assessments and laboratory tests, and the molecular RASopathy diagnosis by NGS panel and/or Sanger sequencing of target genes.
Due to the observational nature of the study, enrolled patients are treated according to clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 8 Years 至 35 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at enrollment between 8 and 35 years, extremes included;
- •Molecularly confirmed clinical diagnosis of RASopathy;
- •Complete pubertal development;
- •Obtaining informed consent for participation in the study and processing of personal data.
排除标准
- 未提供
结局指标
主要结局
Age of pubertal onset in males and females in all different genotypes
时间窗: at baseline
years, months
Proportion of males and females with delayed puberty in all different genotypes
时间窗: at baseline
percentage %
Age at the time of the presence of dosable serum LH (≥0,1 U/L) in males and females in all different genotypes
时间窗: at baseline
years, months
Peak Height Velocity in males and females in all different genotypes
时间窗: at baseline
cm/year
Age at time of presence of dosable serum estradiol (>15 pg/ml) in females in all different genotypes
时间窗: at baseline
years, months
Age at time of presence of dosable serum testosterone (>0,2 ng/ml) in males in all different genotypes
时间窗: at baseline
years, months
Age of reaching Peak Height Velocity in males and females in all different genotypes
时间窗: at baseline
years, months
Statural gain at puberty in males and females in all different genotypes
时间窗: at baseline
cm
次要结局
- Peak Height Velocity in GH-treated and non-treated patients(at baseline)
- Height at first evaluation, final height, and statural gain at puberty in GH-treated and non-treated patients(at baseline)
- Age of reaching Peak Height Velocity in GH-treated and non-treated patients(at baseline)